Add BrightSurf on Google Email

Science in Space to Cure Disease on Earth—the International Space Station National Lab and NASA announce new funding opportunity

The International Space Station National Laboratory is collaborating with NASA to fund up to $4 million in research addressing significant diseases like cancer, cardiovascular disease, and neurodegenerative disease. The joint solicitation aims to leverage microgravity to improve existing or develop new technologies for health problems ...

Sex and the flu

A team of researchers, led by Jason Shoemaker, are studying the effects of hormones on the immune system's response to the flu. Their goal is to develop targeted therapies based on a person's sex or hormone levels. The study aims to identify the molecules or pathways that affect the cells and begin to develop personalized treatments.

UMass Amherst researchers ID body’s ‘quality control’ regulator for protein folding

UMass Amherst researchers have identified the 'quality control' regulator for protein folding, a crucial process that ensures essential cellular functions. The discovery of this regulator, Sep15, could lead to new treatments targeting misfolded proteins associated with diseases like Alzheimer's and cystic fibrosis.

SourceUniversity of Massachusetts Amherst·JournalProceedings of the National Academy of Sciences·DateAug 12, 2024

From fungi to pharmaceuticals: a milestone for the production of eutyscoparol A and violaceoid C

Researchers from Tokyo University of Science have developed an efficient method to synthesize eutyscoparol A and violaceoid C, two compounds with potential therapeutic properties. The new approach improves yields and simplifies synthesis steps, enabling further research into their pharmacological effects.

SourceTokyo University of Science·JournalAsian Journal of Organic Chemistry·TypeExperimental study·DateAug 9, 2024

Drug shows promise for treating brain tumors resulting from breast cancer, UT Health San Antonio trial reports

A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.

SourceUniversity of Texas Health Science Center at San Antonio·JournalNature Communications·TypeRandomized controlled/clinical trial·DateAug 8, 2024

How fungi elude antifungal treatments

Researchers at Michigan State University characterized how fungi restructure their cell walls to thwart current antifungal medications. The study found that fungi enhance their survival odds by making specific changes to the structure and organization of the components in their cell walls, rendering existing drugs ineffective.

SourceMichigan State University·JournalNature Communications·DateAug 7, 2024

Subclinical hypothyroidism during first half of pregnancy is associated with hypothyroidism 1-5 years after delivery

A new study found that subclinical hypothyroidism diagnosed before 21 weeks of pregnancy is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years after delivery. Women with high TSH values and elevated TPO antibodies were at increased risk.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalThyroid·TypeObservational study·DateAug 2, 2024

Published research from the Parkinson’s Foundation shows genetic variants are more common in people with Parkinson’s disease than originally thought

The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.

SourceParkinson's Foundation·JournalBrain·TypeObservational study·DateJul 29, 2024

New England Journal of Medicine publishes outcomes from practice-changing E1910 trial for patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia

The E1910 trial demonstrated a significant survival advantage with blinatumomab immunotherapy, improving overall and relapse-free survival in patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia. This finding contributed to the recent FDA approval of blinatumomab for these patients.

SourceECOG-ACRIN Cancer Research Group·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJul 24, 2024

'Gene misbehavior' widespread in healthy people

A recent study found that 'gene misbehaviour' is a common phenomenon in the healthy human population, with over half of inactive genes showing misexpression. The researchers used advanced techniques to analyze blood samples from 4,568 healthy individuals and identified mechanisms behind these gene activity errors.

SourceWellcome Trust Sanger Institute·JournalAmerican Journal of Human Genetics·TypeObservational study·DateJul 24, 2024

Effectiveness of using siRNA to treat Huntington’s disease

A new study published in Nucleic Acid Therapeutics found that siRNA reduces huntingtin mRNA levels in the cytoplasm but not in the nucleus of mouse brains, suggesting a limitation in its effectiveness for treating Huntington's disease. The research highlights the importance of understanding the structure and function of nuclear RNA to ...

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 22, 2024

Scientists pinpoint new drug target for RSV

Scientists at Trinity College Dublin have identified a key biological pathway, the JAK/STAT pathway, that RSV suppresses and prevents immune system igniters from activating. This discovery provides a promising new target for therapeutic immune restoration and could lead to significant impact in treating RSV infections.

SourceTrinity College Dublin·JournalFrontiers in Immunology·DateJul 19, 2024

New Surgical Infection Society guidelines on the management of intra-abdominal infection

The new guidelines from the Surgical Infection Society offer updated recommendations for antimicrobial agent selection, source control, and treatment of specific pathogens. These evidence-based guidelines aim to improve clinical outcomes and reduce mortality rates from intra-abdominal infections globally.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalSurgical Infections·TypeSystematic review·DateJul 18, 2024

Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer

Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 17, 2024

Off-the-shelf wearable trackers provide clinically-useful information for patients with heart disease

A study published in Nature Medicine found that off-the-shelf wearable trackers can monitor the response to two treatments for atrial fibrillation and heart failure. The devices provided clinically useful information similar to in-person hospital assessments, with a neural network helping to analyze missing data.

SourceUniversity of Birmingham·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJul 15, 2024

A new study reveals the underuse of a key drug in patients with treatment-resistant schizophrenia

A new study analyzed clozapine prescription patterns in patients with first-episode psychosis, finding that approximately 20-30% do not respond to conventional treatments. The use of clozapine can significantly reduce psychotic symptoms and improve quality of life for these patients.

SourceGermans Trias i Pujol Research Institute·JournalSpanish Journal of Psychiatry and Mental Health·TypeExperimental study·DateJul 11, 2024

Researchers find intriguing new tool for tendon healing: nanoparticles for precision drug delivery

A team of researchers has created a new approach to deliver drugs precisely to surgically repaired tendons using nanoparticles, reducing scar tissue formation and improving function. The treatment targets the Acp5 gene, which is highly expressed at the injury site, and delivers medication directly to the healing tendon.

SourceUniversity of Rochester Medical Center·JournalScience Advances·DateJun 27, 2024

AI-based Alphafold: Its potential impact on predictive medicine

AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalAI in Precision Oncology·TypeLiterature review·DateJun 26, 2024

Korea University identifies novel inhibitor HVH-2930 showing promise in overcoming trastuzumab resistance in HER2-positive breast cancer

A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.

SourceKorea University College of Medicine·JournalTheranostics·TypeExperimental study·DateJun 25, 2024

Standardized protocols help hospitals treat strokes faster, WVU research finds

Researchers found that hospitals that implemented standardized protocols from the American Heart Association and American Stroke Association saw significant reductions in stroke treatment times. The protocols, which include specific limits on time between symptom onset and hospital arrival, helped medical teams respond more quickly to ...

SourceWest Virginia University·JournalJournal of Operations Management·DateJun 24, 2024